Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure

Infection

Volumn 39, Issue 6, 2011, Pages 563-569

  Fabbiani, M ^a   Bracciale, L ^a   Ragazzoni, E ^a   Santangelo, R ^a   Cattani, P ^a   Di Giambenedetto, S ^a   Fadda, G ^a   Navarra, P ^a   Cauda, R ^a   De Luca, A ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Drug resistance mutations; Genotypic inhibitory quotient; Human immunodeficiency virus; Non nucleoside reverse transcriptase inhibitors; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; FOSAMPRENAVIR; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF QUANTITATION; MALE; MULTIVARIATE ANALYSIS; PREDICTION; ULTRAVIOLET SPECTROSCOPY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLASMA; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 82655173891     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0183-8     Document Type: Article

References (29)

1. DD Ho AU Neumann AS Perelson W Chen JM Leonard M Markowitz 1995 Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 123 126 7816094 10.1038/373123a0 1:CAS:528:DyaK2MXjtFSrt7o%3D
2. JM Coffin 1995 HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 267 483 489 7824947 10.1126/science.7824947 1:CAS:528:DyaK2MXjsFShu7w%3D
3. C Marzolini A Telenti LA Decosterd G Greub J Biollaz T Buclin 2001 Efavirenz plasma levels can predict treatment failure and central nervous system side-effects in HIV-1-infected patients AIDS 15 71 75 11192870 10.1097/00002030-200101050-00011 1:CAS:528:DC%2BD3MXotlejsA%3D%3D (Pubitemid 32055781)
4. J Durant P Clevenbergh R Garraffo P Halfon S Icard P Del Giudice N Montagne JM Schapiro P Dellamonica 2000 Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the VIRADAPT study AIDS 14 1333 1339 10930147 10.1097/00002030-200007070-00005 1:CAS:528:DC%2BD3cXlsFGluro%3D (Pubitemid 30459505)
5. M Fabbiani S Di Giambenedetto L Bracciale A Bacarelli E Ragazzoni R Cauda P Navarra A De Luca 2009 Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice J Antimicrob Chemother 64 109 117 19398461 10.1093/jac/dkp132 1:CAS:528:DC%2BD1MXntlGgsLw%3D
6. HIVseq program, HIV Drug Resistance Database, Stanford University, Stanford CA USA. Available from: http://hivdb.stanford.edu/pages/algs/HIVseq. html. Accessed 5 Apr 2011.
7. VA Johnson F Brun-Vézinet B Clotet HF Günthard DR Kuritzkes D Pillay JM Schapiro DD Richman 2010 Update of the drug resistance mutations in HIV-1: December 2010 Top HIV Med 18 156 163 21245516
8. HIValg program. HIV Drug Resistance Database, Stanford University, Stanford. Available from: http://hivdb.stanford.edu/pages/algs/HIValg.html. Accessed 5 Apr 2011.
9. A De Luca A Cingolani S Di Giambenedetto MP Trotta F Baldini MG Rizzo A Bertoli G Liuzzi P Narciso R Murri A Ammassari CF Perno A Antinori 2003 Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance J Infect Dis 187 1934 1943 12792870 10.1086/375355 (Pubitemid 36724492)
10. S Di Giambenedetto A De Luca P Villani A Bacarelli E Ragazzoni M Regazzi R Cauda P Navarra 2008 Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure HIV Med 9 239 245 18366448 10.1111/j.1468-1293.2008.00555.x (Pubitemid 351467798)
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 5 Apr 2011.
12. S De Meyer H Azijn D Surleraux D Jochmans A Tahri R Pauwels P Wigerinck MP de Béthune 2005 TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor resistant viruses, including a broad range of clinical isolates Antimicrob Agents Chemother 49 2314 2321 15917527 10.1128/AAC.49.6.2314-2321.2005 (Pubitemid 40734460)
13. JGM Hoefnagel PP Koopmans DM Burger R Schuurman JM Galama 2005 Role of the inhibitory quotient in HIV therapy Antivir Ther 10 879 892 16430193 1:CAS:528:DC%2BD28XhsFKjs74%3D (Pubitemid 43076339)
14. AG Marcelin I Cohen-Codar MS King P Colson E Guillevic D Descamps C Lamotte V Schneider J Ritter M Segondy H Peigue-Lafeuille L Morand-Joubert A Schmuck A Ruffault P Palmer ML Chaix V Mackiewicz V Brodard J Izopet J Cottalorda E Kohli JP Chauvin DJ Kempf G Peytavin V Calvez 2005 Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients Antimicrob Agents Chemother 49 1720 1726 15855487 10.1128/AAC.49.5.1720-1726.2005 1:CAS:528: DC%2BD2MXktFSnsbY%3D (Pubitemid 40631580)
15. I Pellegrin D Breilh JM Ragnaud S Boucher D Neau H Fleury MH Schrive MC Saux JL Pellegrin E Lazaro M Vray 2006 Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar Study) Antivir Ther 11 421 429 16856615 1:CAS:528:DC%2BD28XnsVCksr4%3D (Pubitemid 44024849)
16. I Pellegrin L Wittkop LM Joubert D Neau D Bollens M Bonarek PM Girard H Fleury B Winters MC Saux JL Pellegrin R Thiébaut 2008 Breilh D; ANRS Co3 Aquitaine Cohort. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA Study) Antivir Ther 13 271 279 18505178 1:CAS:528:DC%2BD1cXlslWmur8%3D (Pubitemid 351535378)
17. I Pellegrin D Breilh G Coureau S Boucher D Neau P Merel D Lacoste H Fleury MC Saux JL Pellegrin E Lazaro F Dabis R Thiébaut 2007 ANRS Co3 Aquitaine Cohort. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients Antimicrob Agents Chemother 51 1473 1480 17296739 10.1128/AAC.00481-06 1:CAS:528:DC%2BD2sXktlOjtbk%3D (Pubitemid 46586831)
18. D Breilh I Pellegrin A Rouzés K Berthoin F Xuereb H Budzinski M Munck HJ Fleury MC Saux JL Pellegrin 2004 Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study) AIDS 18 1305 1310 15362663 10.1097/00002030-200406180-00009 1:CAS:528:DC%2BD2cXmtlyqtb8%3D (Pubitemid 38822709)
19. L Valer C De Mendoza V Soriano 2005 Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients J Med Virol 77 460 464 16254964 10.1002/jmv.20477 1:CAS:528:DC%2BD2MXht1els7rF (Pubitemid 41609583)
20. DG De Requena S Bonora A Calcagno A D'Avolio M Siccardi S Fontana MG Milia M Sciandra S Garazzino A Di Garbo L Baietto L Trentini G Di Perri 2008 Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens Antimicrob Agents Chemother 52 1066 1071 18160524 10.1128/AAC.01063-07 (Pubitemid 351358390)
21. R Murri A Ammassari K Gallicano A De Luca A Cingolani D Jacobson AW Wu A Antinori 2000 Patient-reported nonadherence to HAART is related to protease inhibitor levels J Acquir Immune Defic Syndr 24 123 128 10935687 10.1097/00042560-200006010-00006 1:CAS:528:DC%2BD3cXlvFelt78%3D (Pubitemid 30640957)
22. Fabbiani M, Di Giambenedetto S, Ragazzoni E, Cingolani A, Fanti I, Bracciale L, Colafigli M, Tamburrini E, Navarra P, Cauda R, De Luca A, Murri R. Comparison of self-reported adherence and therapeutic drug monitoring in the late HAART era. 12th European AIDS Conference (EACS 2009). Cologne, Germany. Abstract PE 10.1/8.
23. EM Gardner WJ Burman JF Steiner PL Anderson DR Bangsberg 2009 Antiretroviral medication adherence and the development of class-specific antiretroviral resistance AIDS 23 1035 1046 19381075 10.1097/QAD. 0b013e32832ba8ec
24. KM Berg JH Arnsten 2006 Practical and conceptual challenges in measuring antiretroviral adherence J Acquir Immune Defic Syndr 43 Suppl 1 S79 S87 17133207
25. DR Bangsberg TC Porco C Kagay ED Charlebois SG Deeks D Guzman R Clark A Moss 2004 Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates J Infect Dis 190 162 165 15195256 10.1086/420790 1:CAS:528:DC%2BD2cXmt1yht7w%3D (Pubitemid 38858417)
26. MJ Kozal KH Hullsiek RD Macarthur M Berg-Wolf G Peng Y Xiang JD Baxter J Uy EE Telzak RM Novak Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 2007 The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies HIV Clin Trials 8 357 370 18042501 10.1310/hct0806-357 (Pubitemid 350305210)
27. SA Riddler R Haubrich AG Di Rienzo L Peeples WG Powderly KL Klingman KW Garren T George JF Rooney B Brizz UG Lalloo RL Murphy S Swindells D Havlir JW Mellors AIDS Clinical Trials Group Study A5142 Team 2008 Class-sparing regimens for initial treatment of HIV-1 infection N Engl J Med 358 2095 2106 18480202 10.1056/NEJMoa074609 1:CAS:528:DC%2BD1cXlvFCktb8%3D (Pubitemid 351679596)
28. Z Yang R Morrison C Oates J Sarria J Patel A Habibi R Seyedjafari P Hu A Lennon A Li J Dong 2008 HIV-1 genotypic resistance testing on low viral load specimens using the Abbott ViroSeq HIV-1 genotyping system Labmedicine 39 671 673
29. Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; on behalf of the SEHERE consortium (2011). Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother 66:1886-96.